Search
Doxycycline
go.drugbank.com/drugs/DB00254ApprovedInvestigationalVet approvedDoxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generatio...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsAnagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigationalAnagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsCarmustine
go.drugbank.com/drugs/DB00262ApprovedInvestigationalA cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: CARM SPAL-P® 100Argatroban
go.drugbank.com/drugs/DB00278ApprovedInvestigationalArgatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFlucloxacillin
go.drugbank.com/drugs/DB00301ApprovedInvestigationalWithdrawnAntibiotic analog of cloxacillin.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersVoxelotor
go.drugbank.com/drugs/DB14975ApprovedVoxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesCasimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigationalDuchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and cardiac function and is invariably ...
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsAvacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigationalAnti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified by the presence of ANCAs in th...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalPemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. FGFRs ga...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTelisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigationalTelisotuzumab vedotin is an antibody-drug conjugate comprising telisotuzumab, a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting agent, via a protea...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors